FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

被引：0
|
作者：
Lacombe, C. [1 ]
Perrier, M. [2 ]
Hentic, O. [1 ]
Brixi, H. [2 ]
Rebours, V [1 ]
Cadiot, G. [2 ]
Ruszniewski, P. [1 ]
de Mestier, L. [1 ]
机构：
[1] Univ Paris, Beaujon Hosp, APHP Nord, Dept Gastroenterol Pancreatol, Clichy, France
[2] Univ Reims, Robert Debre Hosp, Dept Hepatogastroenterol & Digest Oncol, Reims, France
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
neuroendocrine tumor; antiangiogenic therapy; vegf; well-differentiated;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I17
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [1] FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors
    Lacombe, C.
    Perrier, M.
    Hentic, O.
    Brixi, H.
    Rebours, V.
    Cadiot, G.
    Ruszniewski, P.
    de Mestier, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S621 - S621
  • [2] FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
    Lacombe, Caroline
    Perrier, Marine
    Hentic, Olivia
    Brixi, Hedia
    De Rycke, Ophelie
    Cros, Jerome
    Rebours, Vinciane
    Cadiot, Guillaume
    Ruszniewski, Philippe
    De Mestier, Louis
    IEEE ACCESS, 2023, 11
  • [3] FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
    Lacombe, Caroline
    Perrier, Marine
    Hentic, Olivia
    Brixi, Hedia
    De Rycke, Ophelie
    Cros, Jerome
    Rebours, Vinciane
    Cadiot, Guillaume
    Ruszniewski, Philippe
    de Mestier, Louis
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 (01)
  • [4] Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors
    Oziel-Taieb, Sandrine
    Zemmour, Christophe
    Raoul, Jean-Luc
    Mineur, Laurent
    Poizat, Flora
    Charrier, Nathalie
    Piana, Gilles
    Cavaglione, Gerard
    Niccoli, Patricia
    ANTICANCER RESEARCH, 2021, 41 (04) : 2071 - 2078
  • [5] Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors
    Venook, A. P.
    Ko, A. H.
    Tempero, M. A.
    Uy, J.
    Weber, T.
    Korn, M.
    Bergsland, E. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] What is the optimal duration of folfox-bevacizumab in metastatic colorectal cancer (mCRC)?
    Rahal, M.
    Hassan, E.
    Shakir, S.
    Meshikhes, M.
    Ramadan, R.
    El hadi, S. M.
    Al mulla, A.
    Al Manaa, A.
    Abdelwarith, A.
    Al Faraj, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 38 - 38
  • [7] Array CGH analysis of paired metastatic biopsies obtained pre-treatment and at resistance to FOLFOX-bevacizumab in metastatic CRC patients
    Diaz, Z.
    Przybytkowski, E.
    Lan, C.
    McNamara, S.
    Aguilar-Mahecha, A.
    Camlioglu, E.
    Gologan, A.
    Batist, G.
    Basik, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S33 - S33
  • [8] Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Pintova, Sofya
    Dharmupari, Sirish
    Moshier, Erin
    Zubizarreta, Nicole
    Ang, Celina
    Holcombe, Randall F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 591 - 598
  • [9] Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
    Hurwitz, Herbert, I
    Tan, Benjamin R.
    Reeves, James A.
    Xiong, Henry
    Somer, Brad
    Lenz, HeinzJosef
    Hochster, Howard S.
    Scappaticci, Frank
    Palma, John F.
    Price, Richard
    Lee, John J.
    Nicholas, Alan
    Sommer, Nicolas
    Bendell, Johanna
    ONCOLOGIST, 2019, 24 (07): : 921 - 932
  • [10] Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen
    Limagne, Emeric
    Euvrard, Romain
    Thibaudin, Marion
    Rebe, Cedric
    Derangere, Valentin
    Chevriaux, Angelique
    Boidot, Romain
    Vegran, Frederique
    Bonnefoy, Nathalie
    Vincent, Julie
    Bengrine-Lefevre, Leila
    Ladoire, Sylvain
    Delmas, Dominique
    Apetoh, Lionel
    Ghiringhelli, Francois
    CANCER RESEARCH, 2016, 76 (18) : 5241 - 5252
12345